Bryn Mawr Capital Management LLC Has $232,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Bryn Mawr Capital Management LLC grew its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 7.1% in the fourth quarter, HoldingsChannel reports. The fund owned 9,100 shares of the biopharmaceutical company’s stock after acquiring an additional 600 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Royalty Pharma were worth $232,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Brooklyn Investment Group boosted its holdings in shares of Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 877 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 943 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 997 shares during the last quarter. Finally, Spire Wealth Management boosted its holdings in shares of Royalty Pharma by 377.6% in the 4th quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 1,699 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Down 0.0 %

Shares of Royalty Pharma stock opened at $33.37 on Friday. The business has a fifty day simple moving average of $29.89 and a two-hundred day simple moving average of $28.12. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a market capitalization of $19.24 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 2.31 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.22 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.64%. Royalty Pharma’s dividend payout ratio (DPR) is presently 60.69%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on RPRX shares. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.